All manuscripts
Publications CAR T Cells NK Cells G-Rex®6 Well Plate

Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma

Published Journal Nature Communications

Share
15 pages Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma — Nature Communications, 2020

Overview

This study demonstrates that anti-CD147 CAR-T and CAR-NK cells effectively kill hepatocellular carcinoma cells. To minimize toxicity, a logic-gated GPC3-synNotch system was developed. Transduced NK cells were maintained and expanded in G-Rex® 6 multi-well cell culture plates with IL-2.

What this paper found

T cells and NK cells engineered with a CAR against CD147 (Basigin) killed hepatocellular carcinoma cells selectively and controlled tumors in mice. CD147 was highly upregulated in HepG2 and SK-Hep1 cells relative to PBMCs, and HCC tissue stained strongly positive compared with healthy liver. CD147-CAR primary T cells, primary NK cells and NK-92MI cells lysed HCC cell lines, with decreased lysis of CD147-knockout lines. In SK-Hep1 xenograft NSG mice, CD147-CAR T and NK cells suppressed tumor growth and prolonged survival, and in a patient-derived xenograft model, median survival with CD147-CAR-NK-92MI cells was 63 days versus about 42 days in controls. A GPC3-synNotch-gated CD147-CAR selectively killed dual-antigen cells and caused no severe on-target/off-tumor toxicity in human CD147 transgenic mice.

Note: The work is preclinical (cell lines, xenograft, patient-derived xenograft and transgenic mouse models); the authors state that on-target/off-tumor toxicity should be tested in future clinical trials.

In conclusion, these findings support the therapeutic potential of CD147-CAR-modified immune cells for HCC patients. — Hsiang-chi Tseng, Wei Xiong, Saiaditya Badeti, Yan Yang, Minh Ma, Ting Liu, Carlos A. Ramos, Gianpietro Dotti, Luke Fritzky, Jie-gen Jiang, Qing Yi, James Guarrera, Wei-Xing Zong, Chen Liu, Dongfang Liu, Nature Communications

Study details

Authors
Hsiang-chi Tseng, Wei Xiong, Saiaditya Badeti, Yan Yang, Minh Ma, Ting Liu, Carlos A. Ramos, Gianpietro Dotti, Luke Fritzky, Jie-gen Jiang, Qing Yi, James Guarrera, Wei-Xing Zong, Chen Liu, Dongfang Liu
Institution
Department of Pathology, Immunology and Laboratory Medicine, Rutgers University-New Jersey Medical School, Newark, NJ, USA · Center for Translational Research in Hematologic Malignancies, Houston Methodist Cancer Center, Houston Methodist Research Institute, Houston, TX, USA · Department of Medicine, Baylor College of Medicine, Houston, TX, USA · Department of Microbiology and Immunology and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA · Imaging core facility, Rutgers University-New Jersey Medical School, Newark, NJ, USA · Department of Surgery, New Jersey Medical School, Rutgers-The State University of New Jersey, Newark, NJ, USA · School of Pharmacy, Rutgers-The State University of New Jersey, Piscataway, NJ, USA · Center for Immunity and Inflammation, New Jersey Medical School, Rutgers-The State University of New Jersey, Newark, NJ, USA
Journal
Nature Communications
Year
2020
PMID / PMC
PMID: 32968061 · PMC
G-Rex® model(s)
G-Rex®6 Well Plate
Cell type(s)
CAR T Cells, NK Cells
Application area
Solid tumor
Study phase
Preclinical

How G-Rex® was used

Primary NK cells were harvested on day 7 of expansion and transduced with CD147-CAR retrovirus in RetroNectin-coated plates. Two days later the cells were moved into G-Rex® 6 multi-well cell culture plates and maintained in 35 mL of complete NK culture medium containing 200 U/mL IL-2. The medium was changed every 3–4 days, and 2 × 10^7 cells were kept in each well at each passage. Total cells were counted by trypan blue exclusion, and NK cell percentage and CAR expression were checked by flow cytometry.

Explore related

Full citation

Tseng HC, Xiong W, Badeti S, et al. Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. Nat Commun. 2020;11(1):4810.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →